Abstract
INTRODUCTION
Wilson's disease (WD) is an autosomal recessive disorder of copper metabolism resulting in the pathological accumulation of copper in various tissues and organs, predominantly the liver, brain, cornea, and kidneys. Toxic copper accumulation in these tissues and organs may contribute to a variety of clinical conditions, producing neurological, psychiatric, and hepatic symptoms. WD is lethal if left untreated. [1] [2] [3] Current treatment regimens include copper chelators to promote copper excretion (D-penicillamine, trientine) and zinc salts to reduce copper absorption. Although various studies have documented its efficacy, D-penicillamine causes serious toxicity, resulting in neurological deterio-ration in about 10%-50% of WD patients during the initial phase of treatment. As an alternative, trientine and tetrathiomolybdate have been introduced, but they are costly and their unavailability restricts their applicability in China. Zinc, an anti-copper agent, cannot excrete large amounts of copper, and some WD patients do not tolerate it because it causes gastric irritation. [1] [2] [3] [4] Despite major advances in understanding the disease and its treatment methods, significant controversy still exists regarding the optimal medical therapy, especially in WD patients with neurological symptoms. 5 Gandouling tablet, a Traditional Chinese Medicine produced by our WD Center, has been used to remove copper from WD patients for several decades. The preliminary evidence from clinical studies suggest that Gandouling has a significant decoppering capacity without causing adverse reactions in WD patients. [6] [7] [8] [9] In this study, we investigated combination therapy with low-dose D-penicillamine plus Gandouling in the treatment of WD to observe its safety and efficacy.
METHODS

Patients
WD patients with neurological symptoms were recruited from the Neurological Department, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine between 2013 and 2015. The WD diagnosis was based on characteristic clinical manifestations, a positive family history, a low serum ceruloplasmin (CER) level (< 0.2 g/L), elevated 24-h urinary copper (24-h UC) excretion (> 100 µg/24 h), elevated liver copper (> 250 µg/g dry weight), presence of a Kayser-Fleischer (K-F) ring, elevated 24-h UC excretion following administration of 2 × 500-mg doses of D-penicillamine (> 1600 µg/24 h), and magnetic resonance imaging (MRI) of the brain. The patients also had to meet the WD diagnostic criteria established at the 8th International Meeting on Wilson Disease. 10 All of the patients included in this study were newly diagnosed and had not received any anti-copper treatment before this study. Excluded from the study were patients with hepatic disease or who were asymptomatic; those with severe jaundice, refractory ascites, or other advanced liver disease; those with a severe psychiatric disorder; those who were pregnant or lactating; and those with allergies to the trial medicines. The institutional review board of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine approved this study and the written consent procedure. Each patient gave informed written consent to be included in this study.
Treatment
The 103 WD patients recruited in our study were divided into a treatment group and a control group. The treatment group received anti-copper therapy with a combination of Gandouling (80 mg/kg) and low-dose D-penicillamine (10 mg/kg), whereas the control group was treated with conventional-dose D-penicillamine (20 mg/kg) monotherapy. D-penicillamine (0.125 g, SPH Sine Pharmaceutical Laboratories Co., Ltd., Shanghai, China) was commenced at 5 mg·kg
, gradually increasing to 10 or 20 mg·kg 
Analytical assessment
Baseline characteristics, including age, sex, K-F rings, CER, neurological symptoms, and the course of disease, were recorded. Leukocyte (white blood cell, WBC) and platelet (PLT) counts were monitored before treatment and at 1 year after treatment. Liver function, represented with aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB), and prothrombin time (PT) in serum or plasma, were measured before treatment and at 6 months and 1 year after treatment. The 24-h UC was monitored before treatment and at 4 weeks, 6 months, and 1 year after treatment. To assess the changes in neurological symptoms, the Global Assessment Scale (GAS) 11 was applied to each patient before and 1 year after treatment. The GAS had been shown to be an appropriate tool to monitor disease progression and treatment response in WD patients, and it has now been well utilized in clinical assessment of WD. The scale contains two tiers, including WD-related disability and WD-related neurological dysfunction. A total score equal to 0 indicates the absence of neurological signs, and a total score of 1-56 indicates the increasing severity of neurological impairment. In addition, the frequency and type of complications associated with the treatment and control groups were recorded. All the patients were followed up for 1 year. Liver function was tested using an automatic biochemistry analyzer (H7600; Hitachi, Tokyo, Japan). WBC and PLT counts were determined by flow cytometry analysis (XN-9000 blood analysis pipeline; Sysmex, Kobe, Japan). The 24-h UC level was assessed by atomic absorption spectrophotometry (spectrum analyzer BH5500s; Beijing Bohui Innovation Technology Co., Ltd., Beijing, China).
Statistical analysis
Statistical analyses were performed using the statistical software package SPSS 22.0 (IBM Corp., Armonk, NY, USA). Data are expressed as the mean ± standard deviation ( x ± s). Student's t-test, the one-factor, or test was used. For normally distributed variables, the unpaired Student's t-test was used for comparisons between the two groups and the paired Student's t-test to assess differences before and after treatment. Differences between various time points or among groups were analyzed by using the analysis of variance. The χ 2 test was used for classified data. Differences were considered significant at P < 0.05.
RESULTS
Baseline patient characteristics
The treatment group consisted of 30 male and 23 female patients with ages ranging from 14 to 53 years [average (28 ± 9) years]. The control group included 31 male and 19 female patients with ages ranging from 15 to 59 years [average (28 ± 10) years]. The mean times between the first clinical symptom and the definitive diagnosis in the treatment and the control groups were (8 ± 6) and (8 ± 5) years, respectively. The neurological manifestations of the 120 WD patients included dysarthria, tremor, drooling, dystonia, incoordination, dysphagia, and spasticity. The presence of K-F rings was observed in 51 patients (96.22%) in the treatment group and 48 patients (96.00% ) in the control group. All of the WD patients recruited into our study showed low serum CER (< 0.2 g/L) and elevated 24-h UC excretion (> 100 µg/24 h). Before treatment, the patients' sex, age, K-F rings, CER, 24-h UC, and the course of disease were similar between the two groups.
Blood cell counts
No major differences were noted in WBC and PLT counts between the two groups at the start of therapy (P > 0.05). After treatment, the WBC and PLT counts remained stable in the treatment group at their 1-year follow-up when compared with those of newly diagnosed cases (P > 0.05). In the control group, however, the WBC counts had obviously decreased at 1 year after treatment, with a significant difference between the counts before and after treatment at 1 year (P < 0.05). The PLT counts were mildly decreased in the control group after monotherapy with conventional-dose D-penicillamine for 1 year, but no significant difference was found between before and after treatment at 1 year (P > 0.05) ( Table 2 ).
Liver function
The serum concentrations of ALT, AST, TB, and PT of both groups at the start of therapy and by 6 months and 1 year after treatment are presented in Table 3 . The values were similar between the two groups before treatment (P > 0.05). After treatment, no significant changes were observed in ALT, AST, TB, or PT in the control group at each of the follow-up points (P > 0.05). In contrast, in the treatment group, the four markers reflecting liver function (ALT, AST, TB, PT) had obviously decreased by 6 months and 1 year (P < 0.05). In addition, the serum concentrations of ALT, AST, and TB were significantly lower in the treatment group than in the control group at 6 months and 1 year after treatment (P < 0.05). As for liver function, among 20 WD patients in the treatment group with initial hepatic symptoms, 17 patients (85%) showed alleviation after treatment, 2 (10%) remained stable, and 1 (5% ) showed hepatic deterioration. In contrast, among the 25 WD patients with initial hepatic symptoms in the control group, 10 (68% ) showed alleviation after treatment, 3 (12% ) remained stable, and 5 (20%) showed hepatic deterioration. 
CER and 24-h UC
Serum CER levels in both groups remained constant during the treatment period compared with that of newly diagnosed patients (P > 0.05), and the value of CER was similar between the two groups (P > 0.05).
The 24-h UC excretion was sharply elevated after treatment in both groups, reaching its peak by 4 weeks after treatment. It then gradually decreased at the 6-month and 1-year follow-ups. However, the 24-h UC levels at 6 months and 1 year after treatment were still significantly higher than those before treatment in both groups (P < 0.05). No statistically significant differences in 24-h UC excretion were noted between the treatment and control groups (P > 0.05) ( Table 4) .
Neurological outcome
In the treatment group, 46 WD patients with neurological symptoms improved 1 year after treatment, 6 had stabilized, and 1 suffered worse symptoms. In the control group, 26 WD patients with neurological symptoms had improved 1 year after treatment, 10 experienced a stable neurological condition, and 14 suffered deterioration. Quantitative analysis of the neurological symptoms with GAS showed that the neurological symptoms were similar between the two groups before treatment (P > 0.05). The total GAS scores at 1 year after treatment showed significant changes in the control group compared with newly diagnosed cases (P < 0.05), and they had significantly improved in the treatment group at 1 year (P < 0.05). In addition, the total GAS scores in the treatment group were significantly lower than those in the control group at 1 year after treatment (P < 0.05) ( Table 5 ). group there was neurological deterioration in 8 cases (16%), hepatic worsening in 5 cases (10%), poor appetite in 2 cases (4% ), abdominal discomfort in 5 cases (10% ), leukocytopenia in 5 cases (10% ), and joint pain in 5 cases (10%) ( Table 6) .
Side effects
DISCUSSION
In the current study, our results confirmed the safety and efficacy of combination therapy with Gandouling plus low-dose D-penicillamine as initial treatment in WD patients with neurological symptoms during the 1-year follow-up period. Among the WD patients in the combined-therapy group, 98.11% achieved an improved or stable neurological condition paralleled by a significantly improved GAS score. In addition, their WBC and PLT counts stabilized, and their liver function had either improved or remained stable. The combined therapy also obviously promoted 24-h UC excretion. Finally, we did not observe any immediate severe adverse effects. Only 15.09% of these WD patients experienced adverse reactions, including neurological deterioration in 1 case (1.89% ), hepatic worsening in 1 case (1.89%), poor appetite in 3 cases (5.66%), abdominal discomfort in 2 cases (3.77%), and joint pain in 1 case (1.89%). In contrast, among the WD patients given conventional-dose D-penicillamine alone as their initial treatment, 16% suffered neurological deterioration, and 10% of the patients experienced hepatic worsening. In addition, various side effects appeared in approximately 60% of the patients treated by conventional-dose D-penicillamine monotherapy. Although D-penicillamine has powerful decoppering ability, it also occasionally causes side effects, including bone marrow depression, anemia/leukopenia, immunological lesions, and even paradoxical symptom worsening. 1, 3, 11 In the current study, the incidence of side effects was as high as 60% in the patients given conventional-dose D-penicillamine alone, with neurological deterioration observed in 16% of these WD patients, which is consistent with other reports in the literature. [1] [2] [3] 11 Thus, low-dose D-penicillamine has been recommended for the initial treatment of WD patients with neurological symptoms to decrease its frequent side effects. 12 Consequently, no initial neurological deterioration and few side effects induced by D-penicillamine were observed. The decoppering capacity, however, decreased by using low-dose D-penicillamine. Zinc, another decoppering agent, cannot cause excretion of large amounts of copper, and long-term, high-dose zinc are not well tolerated by some WD patients because of gastric irritation and myeloneuropathy. 11, 13, 14 Traditional Chinese Medicine has made great progress in the treatment of WD, especially with the Gandouling tablet produced by our WD Center. Gandouling has been used for decoppering in WD patients for several decades. The preliminary evidence from clinical studies suggest that Gandouling has substantial decoppering capacity in WD patients without causing adverse reactions. [7] [8] [9] Therefore, the combination of low-dose D-penicillamine and Gandouling was used to improve treatment efficacy in the present study. Gandouling is mainly composed of Dahuang (Radix Et Rhizoma Rhei Palmati), Huanglian (Rhizoma Coptidis) and Huangqin (Radix Scutellariae Baicalensis). Dahuang (Radix Et Rhizoma Rhei Palmati) can increase copper excretion and decrease intestinal copper absorption by stimulating the intestinal wall to promote intestinal evacuation. There is a high content of zinc in Huanglian (Rhizoma Coptidis). Thus, Huanglian (Rhi- zoma Coptidis) could inhibit intestinal absorption of copper. Gandouling can promote bile secretion, increase the formation of bile, and increase bile copper excretion. Consequently, Gandouling has a significant decoppering capacity. 6, 7 Herein, 24-h UC excretion was promoted by the combined therapy, and the 24-h UC values are similar to those in the control group given conventional dose D-penicillamine monotherapy at the 1-year follow-up. Previous studies found that Gandouling could have an anti-fibrosis effect, thereby protecting liver function. 9 We also show the long-term beneficial effect of the combined therapy on liver function in WD patients. Liver function was improved or remained stable in 98.11% of the WD patients treated by Gandouling plus low-dose D-penicillamine, which was significantly superior to the reaction in the control group. Additionally, our study showed that the incidence of initial neurological deterioration in the WD patients caused by the combined therapy was obviously lower than that in the control group, which may be associated with the neuroprotective effect of Huangqin (Radix Scutellariae Baicalensis). 15 In conclusion, the combination therapy of Gandouling plus low-dose D-penicillamine, as initial therapy for WD patients, effectively alleviated neurological symptoms and improved liver function in those with neurological symptoms. The combined therapy had a powerful decoppering ability. In addition, only 15.09% of the WD patients experienced adverse reactions, which included neurological deterioration in 1 case (1.89% ) and hepatic worsening in 1 case (1.89%), a lower incidence than was seen in the control group treated with conventional-dose D-penicillamine monotherapy. Our study confirmed the safety and efficacy of the combination therapy with Gandouling plus low-dose D-penicillamine as the initial treatment in WD patients with neurological symptoms at the 1-year follow-up. A study with a longer follow-up and a larger sample size would be useful to confirm the effect of the combination therapy for WD patients with neurological symptoms.
